NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free NEPH Stock Alerts $2.11 -0.08 (-3.65%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.11▼$2.1550-Day Range$1.99▼$2.3652-Week Range$1.32▼$4.04Volume4,175 shsAverage Volume13,879 shsMarket Capitalization$22.24 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Nephros alerts: Email Address Nephros MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside137.0% Upside$5.00 Price TargetShort InterestHealthy0.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 3 Articles This WeekInsider TradingAcquiring Shares$123,160 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.86 out of 5 starsMedical Sector376th out of 915 stocksSurgical & Medical Instruments Industry50th out of 98 stocks 3.5 Analyst's Opinion Consensus RatingNephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNephros has only been the subject of 1 research reports in the past 90 days.Read more about Nephros' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.01% of the float of Nephros has been sold short.Short Interest Ratio / Days to CoverNephros has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nephros has recently decreased by 81.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNephros does not currently pay a dividend.Dividend GrowthNephros does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NEPH. Previous Next 3.4 News and Social Media Coverage News SentimentNephros has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nephros this week, compared to 1 article on an average week.Search Interest1 people have searched for NEPH on MarketBeat in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nephros insiders have bought more of their company's stock than they have sold. Specifically, they have bought $123,160.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.10% of the stock of Nephros is held by insiders.Percentage Held by Institutions41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nephros' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Nephros is -15.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nephros is -15.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNephros has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nephros' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. Just take a look: Claim your free seat by clicking here now. About Nephros Stock (NASDAQ:NEPH)Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More NEPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEPH Stock News HeadlinesMay 17, 2024 | insidertrades.comRobert R. Jr. Banks Acquires 50,000 Shares of Nephros, Inc. (NASDAQ:NEPH) StockJune 9, 2024 | americanbankingnews.comNephros (NASDAQ:NEPH) Shares Down 0.9% May 17, 2024 | finance.yahoo.comInsider Buying: President and CEO Banks Robert R. Jr. Acquires 50,000 Shares of Nephros Inc (NEPH)May 13, 2024 | finance.yahoo.comEarnings Update: Nephros, Inc. (NASDAQ:NEPH) Just Reported And Analysts Are Trimming Their ForecastsMay 11, 2024 | markets.businessinsider.comNephros: Buy Rating Affirmed Amid Solid Performance and Growth ProspectsMay 9, 2024 | finance.yahoo.comNephros Announces Financial Results for Quarter Ended March 31, 2024May 2, 2024 | finance.yahoo.comNephros Schedules First Quarter 2024 Financial Results Conference CallMay 1, 2024 | finance.yahoo.comNephros, Inc. (NEPH)April 23, 2024 | finance.yahoo.comNephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 20, 2024 | finance.yahoo.comNephros, Inc. (NEPH) Interactive Stock Chart - Yahoo FinanceApril 19, 2024 | finance.yahoo.comNephros, Inc.'s (NASDAQ:NEPH) Profit OutlookMarch 11, 2024 | finanznachrichten.deNephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 10, 2024 | finance.yahoo.comNephros Full Year 2023 Earnings: Misses ExpectationsMarch 9, 2024 | markets.businessinsider.comNephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized OperationsMarch 9, 2024 | markets.businessinsider.comNephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy RatingMarch 8, 2024 | realmoney.thestreet.comNephros just upgraded at Benchmark, here's whyMarch 8, 2024 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comNEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | globenewswire.comNephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 6, 2024 | benzinga.comEarnings Outlook For NephrosMarch 6, 2024 | markets.businessinsider.comNephros earnings: here's what to expectFebruary 29, 2024 | globenewswire.comNephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial ResultsJanuary 28, 2024 | finance.yahoo.comWhat Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?January 24, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerJanuary 24, 2024 | finance.yahoo.comRezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerSee More Headlines Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/14/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees31Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+137.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-10.23% Pretax Margin-10.23% Return on Equity-17.01% Return on Assets-12.90% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio2.77 Sales & Book Value Annual Sales$14.06 million Price / Sales1.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book2.64Miscellaneous Outstanding Shares10,544,000Free Float10,112,000Market Cap$22.25 million OptionableNot Optionable Beta1.21 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Robert Banks (Age 49)President, CEO & Director Comp: $474.04kMs. Judy F. Krandel C.F.A. (Age 59)Chief Financial Officer Comp: $147.01kMr. Alfred VargasDirector of OperationsBrianne McGuireDirector of Brand, Marketing & Business DevelopmentVashone R. ThomasVice President of Quality, Regulatory, & Human ResourcesMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Executive Officer of Specialty Renal Products, Inc Comp: $300.18kMr. Greg LucasPresident of Aether Water SystemsMs. Judy MazziniControllerMore ExecutivesKey CompetitorsHealth Sciences Acquisitions Co. 2NASDAQ:HSAQMonogram OrthopaedicsNASDAQ:MGRMPro-DexNASDAQ:PDEXInspireMDNYSE:NSPRenVVeno MedicalNASDAQ:NVNOView All CompetitorsInsiders & InstitutionsArthur H AmronBought 3,000 shares on 5/30/2024Total: $6,720.00 ($2.24/share)Arthur H AmronBought 2,000 shares on 5/28/2024Total: $4,440.00 ($2.22/share)Robert R Jr. BanksBought 50,000 shares on 5/16/2024Total: $112,000.00 ($2.24/share)Mesirow Financial Investment Management Inc.Bought 15,383 shares on 4/26/2024Ownership: 0.146%Robert R Jr. BanksBought 18,000 shares on 12/7/2023Total: $39,600.00 ($2.20/share)View All Insider TransactionsView All Institutional Transactions NEPH Stock Analysis - Frequently Asked Questions Should I buy or sell Nephros stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nephros in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NEPH shares. View NEPH analyst ratings or view top-rated stocks. What is Nephros' stock price target for 2024? 1 brokerages have issued 1 year price targets for Nephros' stock. Their NEPH share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price. View analysts price targets for NEPH or view top-rated stocks among Wall Street analysts. How have NEPH shares performed in 2024? Nephros' stock was trading at $3.46 at the beginning of the year. Since then, NEPH shares have decreased by 39.0% and is now trading at $2.11. View the best growth stocks for 2024 here. Are investors shorting Nephros? Nephros saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 600 shares, a decrease of 81.3% from the May 15th total of 3,200 shares. Based on an average daily volume of 15,300 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's shares are short sold. View Nephros' Short Interest. When is Nephros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our NEPH earnings forecast. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) released its earnings results on Thursday, May, 9th. The company reported ($0.02) EPS for the quarter. The firm earned $3.52 million during the quarter. Nephros had a negative trailing twelve-month return on equity of 17.01% and a negative net margin of 10.23%. Who are Nephros' major shareholders? Nephros' stock is owned by a number of retail and institutional investors. Top institutional investors include Mesirow Financial Investment Management Inc. (0.15%). Insiders that own company stock include Andrew Astor, Arthur H Amron, Robert R Jr Banks, Tom Gwydir and Wesley S Lobo. View institutional ownership trends. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NEPH) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
